8-K: PDS Biotech's Versamune HPV Shows Promise in Clearing Cancer Cells, Phase 3 Trial Planned

PDS Biotechnology announces positive circulating tumor DNA results for Versamune HPV, indicating potential as a broadly effective treatment for HPV16-associated cancers and plans for a Phase 3 trial in HPV16-positive HNSCC.

Summary

• PDS Biotechnology Corporation announced the publication of positive circulating tumor DNA (ctDNA) results for its lead immunotherapy candidate, Versamune HPV.
• The data, published in Clinical Cancer Research, demonstrates Versamune HPV's potential as a treatment for HPV16-associated cancers.
• The trial showed that Versamune HPV, when combined with chemoradiation (CRT), led to greater and earlier clearance of HPV16-positive cancer cells from the bloodstream compared to CRT alone.
• 100% of patients with locally advanced HPV16 cervical cancer treated with Versamune HPV + CRT had no detectable HPV16 ctDNA at 3-4 months, compared to 50% of patients on standard-of-care CRT.
• Undetectable HPV ctDNA at 3-4 months was associated with improved 2-year recurrence-free survival (RFS) of 93% vs only 30% in patients with detectable HPV ctDNA.
• The company plans to initiate a Phase 3 clinical trial for Versamune HPV in HPV16-positive head and neck squamous cell carcinoma (HNSCC) in Q1 2025.
• A total of 66 patients with locally advanced cervical cancer were enrolled, with 49 receiving CRT and 17 receiving a combination of CRT and Versamune HPV.
• Patient blood was collected at baseline, weeks 1, 3, and 5 of CRT, and 3 to 4 months after CRT to measure HPV ctDNA.
• MRI was performed at baseline and before brachytherapy to determine tumor shrinkage.
• Median follow-up was 23 months.
• The strongest predictor of RFS was HPV ctDNA clearance at 3-4 months follow-up, achieving a concordance index score of 0.83.
• The 36-month overall survival (OS) and progression free survival rates were earlier reported to be 100% for the 8 patients in the trial who received 5 doses of Versamune HPV + CRT and an 84.4% 36-month OS rate for 17 patients who received at least 2 doses of Versamune HPV + CRT.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and plans for a Phase 3 trial, indicating a promising outlook for the company and its lead product. However, risks related to future trials and funding are also noted.

Positives

• Versamune HPV demonstrates a strong correlation between ctDNA clearance and improved recurrence-free survival.
• The company is planning to initiate a Phase 3 trial, indicating confidence in the drug's potential.
• The data suggests the possibility of an accelerated regulatory pathway with the FDA.

Risks

• The company's future performance depends on the success of clinical trials and regulatory approvals.
• The company's limited operating history makes it difficult to evaluate its prospects.
• The company depends on additional financing to fund its operations.

Future Outlook

The company plans to initiate a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech's lead investigational targeted immunotherapy Versamune HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.

Management Comments

• Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, stated that combining Versamune HPV with chemoradiation (CRT) was linked to rapid HPV16 ctDNA decline.
• He also believes that the strong correlation between ctDNA and survival may allow for discussions with the FDA regarding an accelerated regulatory pathway.

Industry Context

This announcement is relevant to the field of cancer immunotherapy and HPV-related cancer treatments. The results position PDS Biotech as a potential player in the market for HPV16-positive cancer therapies.

Comparison to Industry Standards

• The 93% 2-year recurrence-free survival (RFS) rate in patients with undetectable HPV ctDNA at 3-4 months compares favorably to standard-of-care CRT alone, which had a 30% RFS rate.
• Competitors in the HPV-related cancer treatment space include companies developing vaccines, immunotherapies, and targeted therapies.
• Key benchmarks include clinical trial outcomes, regulatory approvals, and market share in specific HPV-related cancer indications.

Stakeholder Impact

• Positive results could lead to improved treatment options for patients with HPV16-associated cancers.
• Successful clinical trials and regulatory approvals could increase shareholder value.
• The company's growth could create new employment opportunities.

Next Steps

• Initiation of Phase 3 clinical trial for Versamune HPV in HPV16-positive head and neck squamous cell carcinoma (HNSCC) in Q1 2025.
• Potential discussions with the FDA regarding an accelerated regulatory pathway such as Breakthrough Therapy designation in cervical cancer.

Key Dates

Keywords

Versamune HPV, PDS Biotechnology, ctDNA, HPV16, Cervical Cancer, HNSCC, Immunotherapy, Clinical Trial, Cancer Research